Faruqi & Faruqi Investigates Ultragenyx Securities Litigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy RARE?
Source: PRnewswire
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential securities fraud claims against Ultragenyx Pharmaceutical, urging investors who purchased shares between August 3, 2023, and December 26, 2025, to seek lead plaintiff status in a class action lawsuit by the April 6, 2026 deadline to protect their legal rights.
- Stock Price Plunge: Following Ultragenyx's announcement on July 9, 2025, that its Phase III Orbit study failed to achieve statistical significance, the stock price fell over 25%; further confirmation on December 29, 2025, that both the Orbit and Cosmic studies did not meet primary endpoints led to an additional drop of over 42%, reflecting severe market disappointment in the company's prospects.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives violated federal securities laws by making false and misleading statements regarding clinical trial results, failing to disclose associated risks, which severely undermined investor confidence in the company's future.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Ultragenyx's conduct, including whistleblowers and former employees, to come forward to better protect investor rights and advance the litigation process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.710
Low
35.00
Averages
61.65
High
120.00
Current: 21.710
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Reports Phase 3 Data for DTX301, Stock Declines
- Clinical Trial Results: Ultragenyx's Phase 3 study of DTX301 revealed a significant 18% reduction in 24-hour plasma ammonia levels at week 36 compared to placebo, indicating potential efficacy despite a decline in stock price due to market reactions.
- Patient Responses: Among patients treated with DTX301, eight out of nine with abnormal baseline ammonia levels rapidly achieved normal levels, highlighting the therapy's importance in improving patient health and potentially influencing future treatment options.
- Safety Profile: DTX301 was well tolerated, with common adverse events being mild to moderate hepatic reactions, consistent with prior safety data, which may enhance investor confidence in the drug's clinical application.
- Market Performance: Ultragenyx's stock is currently trading 3.7% below its 20-day simple moving average and has decreased by 46.87% over the past 12 months, indicating bearish momentum in the short term, while analysts maintain a price target of $71.45, reflecting a positive outlook on its long-term potential.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to possible false statements made between August 3, 2023, and December 26, 2025, which may have misled investors and impacted their confidence.
- Stock Price Drop: Following Ultragenyx's announcement on July 9, 2025, that its Phase III Orbit study failed to achieve statistical significance, the stock price plummeted over 25%, indicating a strong market reaction to the disappointing research results.
- Study Failure Impact: On December 29, 2025, Ultragenyx confirmed that both its Phase III Orbit and Cosmic studies did not achieve statistical significance against primary endpoints, causing the stock to drop by more than 42%, reflecting investor pessimism regarding the company's future prospects.
- Investor Rights Protection: Faruq & Faruqi LLP reminds investors that April 6 is the deadline to apply for lead plaintiff status in the federal securities class action, emphasizing the importance of investor participation in legal proceedings and potential compensation opportunities.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Ultragenyx Pharmaceutical Inc. stock between August 3, 2023, and December 26, 2025, can seek lead plaintiff status in a class action lawsuit by April 6, 2026, alleging violations of the Securities Exchange Act of 1934 by the company and its executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx made false and misleading statements throughout the class period, failing to disclose that its Phase III Orbit study did not achieve statistical significance, misleading investors about the company's prospects.
- Stock Price Impact: Following the July 9, 2025 announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock price fell over 25%; after the December 29, 2025 announcement of further study failures, the stock dropped more than 42%, indicating severe damage to investor confidence.
- Legal Process Overview: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can apply to be the lead plaintiff, representing all other members in the lawsuit, which may influence potential future recovery outcomes.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for securities purchased between August 3, 2023, and December 26, 2025, urging affected investors to contact the firm by April 6, 2026, to participate.
- False Statement Allegations: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta (OI), leading to an overly optimistic market perception that misled investors.
- Study Results Revelation: The Phase III ORBIT study revealed that Ultragenyx failed to achieve a statistically significant reduction in annualized fracture rate (AFR), highlighting significant errors in the company's drug efficacy claims, which exacerbated investor losses.
- Legal Implications: As the market learned the truth about Ultragenyx, investors suffered damages, and the Schall Law Firm specializes in securities class action lawsuits to assist affected investors in recovering their losses and protecting their rights.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Litigation
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Ultragenyx Pharmaceutical, urging investors who purchased shares between August 3, 2023, and December 26, 2025, to seek lead plaintiff status by the April 6, 2026 deadline.
- Stock Price Volatility: Following the July 9, 2025 announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%; on December 29, 2025, after revealing that both Orbit and Cosmic studies did not meet primary endpoints, the stock fell more than 42%, reflecting severe market concerns about the company's future.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives violated federal securities laws by making false or misleading statements regarding the clinical trial results, failing to disclose associated risks, which severely undermined investor confidence in their products.
- Investor Rights Protection: Faruq & Faruq LLP encourages affected investors to contact them for information or to participate in the litigation, ensuring their rights are fully protected and potentially securing compensation for their losses.
See More
Ultragenyx's Gene Therapy DTX301 Achieves Key Trial Goal
- Clinical Trial Success: Ultragenyx's gene therapy candidate DTX301 achieved its primary goal in a late-stage trial for the most common urea cycle disorder, with 36-week data showing an ~18% reduction in 24-hour plasma ammonia levels in treated patients, indicating statistical significance and clinical relevance.
- Positive Patient Response: Among nine patients with abnormal ammonia levels, eight swiftly returned to normal after DTX301 treatment, suggesting the therapy's potential to improve patient health outcomes and possibly transform the treatment landscape for OTC deficiency.
- Safety Assessment: While only one patient in the DTX301 group discontinued the trial, compared to two in the placebo group, which included one death, this indicates a relatively higher safety profile for DTX301, with only one hospitalization event for hyperammonemic crises in the treatment group.
- Ongoing Multinational Trial: The trial, involving 37 patients across 10 countries, is set to report secondary endpoint data on the treatment burden of DTX301 in H1 2027, further validating its clinical application potential and possibly opening new market opportunities for Ultragenyx.
See More
Ultragenyx Reports Phase 3 Data for DTX301, Stock Declines
- Clinical Trial Results: Ultragenyx's Phase 3 study of DTX301 revealed a significant 18% reduction in 24-hour plasma ammonia levels at week 36 compared to placebo, indicating potential efficacy despite a decline in stock price due to market reactions.
- Patient Responses: Among patients treated with DTX301, eight out of nine with abnormal baseline ammonia levels rapidly achieved normal levels, highlighting the therapy's importance in improving patient health and potentially influencing future treatment options.
- Safety Profile: DTX301 was well tolerated, with common adverse events being mild to moderate hepatic reactions, consistent with prior safety data, which may enhance investor confidence in the drug's clinical application.
- Market Performance: Ultragenyx's stock is currently trading 3.7% below its 20-day simple moving average and has decreased by 46.87% over the past 12 months, indicating bearish momentum in the short term, while analysts maintain a price target of $71.45, reflecting a positive outlook on its long-term potential.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to possible false statements made between August 3, 2023, and December 26, 2025, which may have misled investors and impacted their confidence.
- Stock Price Drop: Following Ultragenyx's announcement on July 9, 2025, that its Phase III Orbit study failed to achieve statistical significance, the stock price plummeted over 25%, indicating a strong market reaction to the disappointing research results.
- Study Failure Impact: On December 29, 2025, Ultragenyx confirmed that both its Phase III Orbit and Cosmic studies did not achieve statistical significance against primary endpoints, causing the stock to drop by more than 42%, reflecting investor pessimism regarding the company's future prospects.
- Investor Rights Protection: Faruq & Faruqi LLP reminds investors that April 6 is the deadline to apply for lead plaintiff status in the federal securities class action, emphasizing the importance of investor participation in legal proceedings and potential compensation opportunities.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Ultragenyx Pharmaceutical Inc. stock between August 3, 2023, and December 26, 2025, can seek lead plaintiff status in a class action lawsuit by April 6, 2026, alleging violations of the Securities Exchange Act of 1934 by the company and its executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx made false and misleading statements throughout the class period, failing to disclose that its Phase III Orbit study did not achieve statistical significance, misleading investors about the company's prospects.
- Stock Price Impact: Following the July 9, 2025 announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock price fell over 25%; after the December 29, 2025 announcement of further study failures, the stock dropped more than 42%, indicating severe damage to investor confidence.
- Legal Process Overview: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can apply to be the lead plaintiff, representing all other members in the lawsuit, which may influence potential future recovery outcomes.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for securities purchased between August 3, 2023, and December 26, 2025, urging affected investors to contact the firm by April 6, 2026, to participate.
- False Statement Allegations: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta (OI), leading to an overly optimistic market perception that misled investors.
- Study Results Revelation: The Phase III ORBIT study revealed that Ultragenyx failed to achieve a statistically significant reduction in annualized fracture rate (AFR), highlighting significant errors in the company's drug efficacy claims, which exacerbated investor losses.
- Legal Implications: As the market learned the truth about Ultragenyx, investors suffered damages, and the Schall Law Firm specializes in securities class action lawsuits to assist affected investors in recovering their losses and protecting their rights.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Litigation
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Ultragenyx Pharmaceutical, urging investors who purchased shares between August 3, 2023, and December 26, 2025, to seek lead plaintiff status by the April 6, 2026 deadline.
- Stock Price Volatility: Following the July 9, 2025 announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%; on December 29, 2025, after revealing that both Orbit and Cosmic studies did not meet primary endpoints, the stock fell more than 42%, reflecting severe market concerns about the company's future.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives violated federal securities laws by making false or misleading statements regarding the clinical trial results, failing to disclose associated risks, which severely undermined investor confidence in their products.
- Investor Rights Protection: Faruq & Faruq LLP encourages affected investors to contact them for information or to participate in the litigation, ensuring their rights are fully protected and potentially securing compensation for their losses.
See More
Ultragenyx's Gene Therapy DTX301 Achieves Key Trial Goal
- Clinical Trial Success: Ultragenyx's gene therapy candidate DTX301 achieved its primary goal in a late-stage trial for the most common urea cycle disorder, with 36-week data showing an ~18% reduction in 24-hour plasma ammonia levels in treated patients, indicating statistical significance and clinical relevance.
- Positive Patient Response: Among nine patients with abnormal ammonia levels, eight swiftly returned to normal after DTX301 treatment, suggesting the therapy's potential to improve patient health outcomes and possibly transform the treatment landscape for OTC deficiency.
- Safety Assessment: While only one patient in the DTX301 group discontinued the trial, compared to two in the placebo group, which included one death, this indicates a relatively higher safety profile for DTX301, with only one hospitalization event for hyperammonemic crises in the treatment group.
- Ongoing Multinational Trial: The trial, involving 37 patients across 10 countries, is set to report secondary endpoint data on the treatment burden of DTX301 in H1 2027, further validating its clinical application potential and possibly opening new market opportunities for Ultragenyx.
See More
